A summary of IPOs from companies in the biotech and pharma world since December 1, 2018.
December 2018 IPO Filings and Proceeds, Updated 12/28/18
Know of an IPO since Dec. 1, 2018 that we missed? Email us at news@biospace.com.
Related: Check out BioSpace’s October IPO list here and November list here.
| Date | Company Name | Amount (USD) | Company HQ | Research Focus |
|---|---|---|---|---|
| 12/28/18 | Stealth Biotherapeutics | $86.3M Filed | Newton, MA | Novel therapies for diseases involving mitochondrial dysfunction |
| 12/28/18 | TCR2 Therapeutics | $100M Filed | Cambridge, MA | Novel T-cell therapies using multi-format TRuC platform |
| 12/27/18 | Harpoon Therapeutics | $86.3M Filed | San Francisco, CA | T cell engagers that harness the immune system to treat cancer and other diseases |
| 12/21/18 | Gossamer Bio | $264.5M Filed | San Diego, CA | Therapeutics in the disease areas of immunology, inflammation, and oncology |
| 12/21/18 | Hoverink Biotechnologies | $40M Filed | Los Angeles, CA | Opioid alternatives for GI and oncological diseases |
| 12/11/18 | Cannabinoid Biosciences | $50M Filed | Los Angeles, CA | Cannabinoid-based products for a wide range of diseases |
| 12/7/18 | DiaMedica | $16.4M Priced | Minneapolis, MN | DM199, a recombinant human protein, for neurological and kidney diseases |
| 12/7/18 | Synthorx | $131M Priced | La Jolla, CA | Designing and building protein therapeutics to treat cancer and autoimmune disorders |
| 12/6/18 | Moderna | $604.3M Priced | Cambridge, MA | mRNA medicines used to eventually prevent, treat, or cure disease |
| 12/6/18 | Aptorum Group | $30M Priced | Hong Kong | Preclinical pharmaceutical company across a wide range of disease areas |
